Our Pipeline

Advancing innovative antibody therapeutics from discovery through clinical development

6
Programs in Development
3
Clinical Stage Programs
5
Technology Platforms

Development Programs

Active Development
Partnered
CYR-101
Phase I
HER2/TROP2
Solid Tumors
Bispecific ADC
Next-generation bispecific antibody-drug conjugate targeting HER2 and TROP2 for treatment-resistant solid tumors.
CYR-202
Preclinical
CD19/CD3
B-cell Malignancies
T-cell Engager
Novel T-cell engaging bispecific antibody for relapsed/refractory B-cell lymphomas and leukemias.
CYR-303
Phase II
BCMA
Multiple Myeloma
ADC
BCMA-targeted antibody-drug conjugate with proprietary linker-payload technology for multiple myeloma.
CYR-404
Phase I
EGFR/c-MET
NSCLC
Bispecific Antibody
Dual-targeting bispecific antibody for EGFR-mutant non-small cell lung cancer with c-MET amplification.
CYR-505
Preclinical
PD-L1/4-1BB
Solid Tumors
Immunomodulator
Conditional 4-1BB agonist bispecific antibody designed to enhance anti-tumor immunity in PD-L1 positive tumors.
CYR-606
Discovery
FRα
Ovarian Cancer
ADC
Folate receptor alpha-targeted ADC with novel cytotoxic payload for platinum-resistant ovarian cancer.
Discovery
Preclinical
PI
PII
PIII

Partnership Opportunities

We are actively seeking strategic partnerships to advance our pipeline and bring innovative therapies to patients worldwide.